Is psilocybin legal in Australia?

No, not for general use. Psilocybin is a Schedule 9 prohibited substance under Australia's Poisons Standard. Possession, use or supply without specific authorisation is a criminal offence. The only lawful pathway is through TGA-approved Authorised Prescribers — a narrow clinical scheme for specific patient groups, not a general access route.

What is 'functional unblinding' in psychedelic trials?

Functional unblinding happens when trial participants can correctly identify whether they received an active psychedelic compound or a placebo, based on the unmistakable subjective effects of the drug. Studies consistently find that around 80% of psilocybin trial participants guess correctly, which complicates the standard assumption that blinded trials isolate pharmacological effects from participant expectation.

Why can't researchers just use a better placebo?

No currently available compound reliably mimics psilocybin's perceptual effects without having its own significant pharmacological activity. Attempts using niacin, low-dose methylphenidate or sub-perceptual doses of the study drug itself reduce but do not eliminate the unblinding problem. This is an active area of methodological research in the field.

Does the placebo problem mean psychedelic research results are invalid?

Not invalid — but it does mean effect sizes in published studies likely include an unquantified contribution from participant expectation. Researchers themselves acknowledge this openly. It's a reason to read headline results carefully and to support continued methodological refinement, not a reason to dismiss the research entirely.

How does Australia's Authorised Prescriber scheme work for psilocybin?

Since February 2023, certain psychiatrists approved as Authorised Prescribers by the TGA can legally prescribe Schedule 8 psilocybin for specific patient groups in a supervised clinical setting. This is separate from standard pharmacy supply — psilocybin does not appear on the Australian Register of Therapeutic Goods as a registered medicine. The Special Access Scheme provides another narrow individual-patient pathway. Both require significant regulatory oversight.

Placebo Challenges in Psychedelic Research

By Daniel Okoro · 8 June 2026 · 7 min read

red and white mushroom in forest during daytime

Roughly 80% of participants in published psilocybin trials correctly guess whether they received the active compound or the control. That single figure , drawn repeatedly from unblinding questionnaires across multiple studies , sits at the centre of one of psychedelic research's most contested methodological arguments, and it doesn't go away just because the field is exciting.

Before anything else, the legal ground: in Australia, psilocybin remains a Schedule 9 prohibited substance under the Poisons Standard. Possession, use or supply outside a specifically authorised context is a criminal offence. The one narrow lawful channel is the Authorised Prescriber scheme, under which the TGA amended the Poisons Standard in February 2023 to allow certain psychiatrists approved under that scheme to prescribe Schedule 8 psilocybin or MDMA for specific patient groups , under strict conditions, through a registered mental health setting, with no self-administration at home. The Special Access Scheme also exists for individual unregistered therapeutic goods, but the pathways are narrow and heavily supervised. There is no legal avenue for casual or unsupervised use. Full stop.

With that grounding in place, let's look at what the placebo problem actually is; because it's genuinely interesting science.

What blinding means in a clinical trial

In a standard randomised controlled trial, "blinding" means neither the participant nor (in a double-blind design) the researcher knows who received the active compound versus the inert control. Blinding exists to isolate the pharmacological effect from expectation, suggestion and the therapeutic relationship. A participant who knows they've taken the active drug will, quite naturally, interpret their experience through that lens, and that interpretation can itself drive measurable outcomes.

For most pharmaceutical compounds this is achievable. A beta-blocker and its matched placebo look, taste and feel identical. But psilocybin, along with MDMA, ketamine and LSD; produces perceptual effects so distinctive that most people know, usually within an hour, whether they received the real thing. Researchers call this "functional unblinding", and it fundamentally complicates any claim that placebo-controlled psilocybin trials are truly blinded.

The specific challenge with serotonergic psychedelics

Psilocybin is converted in the body to psilocin, which acts primarily as a partial agonist at 5-HT2A receptors, the serotonin receptors most associated with altered sensory perception, changes to default mode network activity and the characteristic subjective effects documented in research accounts. There is currently no known "active placebo" that mimics these effects without itself being pharmacologically significant.

Some research teams have used low-dose niacin (which produces a flushing sensation), low-dose methylphenidate, or sub-perceptual doses of the study compound itself as active comparators. These create some uncertainty but don't fully replicate the signature phenomenology. A 2022 paper in Psychopharmacology by Szigeti and colleagues explored a "self-blinding" microdose methodology specifically to address this, but the design has its own limitations around dosing consistency and self-report bias.

The deeper issue is that expectation and pharmacology are genuinely hard to disentangle here. If a participant expects a profound experience, enters the trial believing in the compound's effects, and then has a profound experience; how much of the measured outcome is pharmacology and how much is a very well-curated expectation response? Honestly, nobody has a clean answer yet.

Why functional unblinding matters for interpreting results

This is where I'd push back gently against some of the more enthusiastic coverage of psychedelic trial results. The unblinding problem doesn't mean the trials are worthless, far from it. What it means is that effect sizes in open-label and even nominally "blinded" psilocybin studies likely contain an unquantified expectation component. That's not a scandal; it's a methodological reality that the field's own researchers have been upfront about. But it does mean we should read the numbers carefully.

Robin Carhart-Harris and colleagues at Imperial College London, whose research underpins much of the current clinical framework, have written explicitly about these limitations. The 2021 NEJM comparison study between psilocybin and a standard antidepressant was widely reported, but the authors themselves noted that the open-label nature of dosing, and the intensive therapeutic support provided alongside the compound, made it impossible to attribute outcomes to pharmacology alone. That's a significant caveat, and it's important that it not get lost in the headline.

I spent a chunk of last Tuesday night going back through the supplementary materials from three recent Phase II studies. The unblinding rates were consistently high. Which, again, isn't a nail in the coffin; but it is a problem that the field needs better tools to address.

Proposed solutions and their trade-offs

Researchers have proposed several approaches, none of them perfect.

Active placebos attempt to produce some physical sensation without the primary psychoactive mechanism. The challenge is that any compound with enough somatic effect to fool participants may have its own pharmacological activity worth controlling for, a circular problem.

Crossover designs, where participants eventually receive both the active compound and the comparator in different sessions, can help with within-subject comparison but don't solve the unblinding issue and introduce carry-over effects.

Expectancy-controlling questionnaires, measuring participant belief about what they received and adjusting statistically; are increasingly used. This approach at least makes the bias visible and quantifiable, even if it can't eliminate it.

Dose-response designs, comparing very low doses against higher doses, sidestep the need for an inert placebo by using the compound itself as its own comparator. This is arguably more honest, though it changes what question the trial is actually answering.

The field's methodologists, including work published through the journal Nature Medicine and through MAPS's open trial documentation, are actively refining these approaches. The pharmacokinetics of psilocin, relatively fast onset, 4–6 hour window in most study reports, minimal residual sedation, make some crossover designs more feasible than with longer-acting compounds, which is one structural advantage.

The therapist blinding problem

There's a second blinding issue that gets less attention: the therapists and guides present during sessions almost certainly know when a participant has received the active compound. Their behaviour, however carefully trained, may subtly differ. Eye contact, tone of voice, how closely they monitor; these small cues can feed back into the participant's experience and into the subjective outcome measures collected afterwards.

Some trials have tried to standardise guide behaviour with scripted protocols and video review, but this is genuinely hard to control. The therapeutic container is, by design, responsive and human. Making it mechanical enough to blind would arguably undermine the very mechanism researchers are interested in.

What this means for Australian regulatory science

The TGA's 2022–2023 scheduling decisions, rescheduling psilocybin from Schedule 9 to Schedule 8 for specific Authorised Prescriber use, were made on the basis of existing international trial data, with explicit acknowledgement that the evidence base is still developing. The TGA's delegate's final decision document from February 2023 notes the limitations of current trial blinding directly in its assessment of evidence quality.

That's actually appropriate regulatory caution. The ARTG listing pathway for any future approved psilocybin product would require the kind of controlled evidence that is currently difficult to generate cleanly; which is part of why no psilocybin product appears on the ARTG as a registered medicine, and why the current access is through prescriber-level pathways rather than standard pharmacy supply.

For anyone reading this who is curious about psychedelic research: the science is genuinely fascinating, the methodological debates are real and ongoing, and the legal framework in Australia is being built in real time. But it is still a framework that treats unauthorised access as a criminal matter. The Authorised Prescriber and Special Access pathways exist for supervised clinical contexts, not personal exploration.

The placebo problem in this field isn't going to be solved quickly. In my view, that's actually fine, it's the kind of friction that makes the science better over time, provided researchers keep naming it rather than papering over it with effect-size headlines.

Sources

, Daniel Okoro, Psychedelic science & law writer

Common questions

Is psilocybin legal in Australia?: No, not for general use. Psilocybin is a Schedule 9 prohibited substance under Australia's Poisons Standard. Possession, use or supply without specific authorisation is a criminal offence. The only lawful pathway is through TGA-approved Authorised Prescribers — a narrow clinical scheme for specific patient groups, not a general access route.
What is 'functional unblinding' in psychedelic trials?: Functional unblinding happens when trial participants can correctly identify whether they received an active psychedelic compound or a placebo, based on the unmistakable subjective effects of the drug. Studies consistently find that around 80% of psilocybin trial participants guess correctly, which complicates the standard assumption that blinded trials isolate pharmacological effects from participant expectation.
Why can't researchers just use a better placebo?: No currently available compound reliably mimics psilocybin's perceptual effects without having its own significant pharmacological activity. Attempts using niacin, low-dose methylphenidate or sub-perceptual doses of the study drug itself reduce but do not eliminate the unblinding problem. This is an active area of methodological research in the field.
Does the placebo problem mean psychedelic research results are invalid?: Not invalid — but it does mean effect sizes in published studies likely include an unquantified contribution from participant expectation. Researchers themselves acknowledge this openly. It's a reason to read headline results carefully and to support continued methodological refinement, not a reason to dismiss the research entirely.
How does Australia's Authorised Prescriber scheme work for psilocybin?: Since February 2023, certain psychiatrists approved as Authorised Prescribers by the TGA can legally prescribe Schedule 8 psilocybin for specific patient groups in a supervised clinical setting. This is separate from standard pharmacy supply — psilocybin does not appear on the Australian Register of Therapeutic Goods as a registered medicine. The Special Access Scheme provides another narrow individual-patient pathway. Both require significant regulatory oversight.